(BRK.A), (BRK.B)
Berkshire Hathaway’s Lubrizol has announced a significant milestone: a drug formulation enabled by its Apisolex™ polymer excipient has entered Phase 1 clinical trials. Launched in 2022, Apisolex is a polyamino acid-based polymer designed to dramatically enhance the solubility of challenging active pharmaceutical ingredients (APIs), specifically those classified as BCS Class II and IV.
Manufactured according to Good Manufacturing Practices (GMP), Apisolex is suitable for a variety of dosage forms, including parenteral administration. Its unique formulation has demonstrated the ability to increase the solubility of certain APIs by up to 50,000 times, making it a valuable tool for the development of hard-to-formulate drugs across multiple therapeutic areas and delivery routes.
Apisolex is currently being evaluated in several programs worldwide, supporting the delivery of APIs that have previously posed significant formulation challenges. Kevin Song, Senior Director of Lubrizol’s Global Pharmaceutical and Nutraceutical Business, emphasized the importance of this development: “The progression to clinical trials of a medicinal product formulated with Apisolex polymer excipient demonstrates its ability to provide differentiated solutions to solubility and bioavailability challenges in parenteral formulations.”
Lubrizol is committed to expanding the global reach of Apisolex and strengthening collaborations with drug manufacturers facing solubility hurdles, paving the way for more effective therapies in the future.
© 2025 David Mazor
Disclosure: David Mazor is a freelance writer focusing on Berkshire Hathaway. The author is long in Berkshire Hathaway, and this article is not a recommendation on whether to buy or sell the stock. The information contained in this article should not be construed as personalized or individualized investment advice. Past performance is no guarantee of future results.